To improve survival and quality of life among the 2.5 million children living with HIV, a comprehensive package of prevention, care and treatment is required. This package should include management of infections such as pneumonia, diarrhoea, malaria and ear infections, as well as common opportunisti...c infections and HIV-related co-morbidities. WHO is developing a series of guidelines on each of these conditions, following the GRADE approach. The document on the management of pneumonia and diarrhoea in HIV-infected infants and children is the first of this series. The recommendations are similar to those for non infected children, but they cover specific aspects related to HIV infection.
more
UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance
You can also register into a free online course
https://www.open.edu/openlearncreate/course/view.php?id=13
This s a systematic review of English language literature from 2000 to 2010 covering spiritual care in end of life care settings which includes spiritual assessment tools and ongoing intervention models.
An Update will be published in late 2018
Historically, the discovery of the sulfa drugs in the 1930s and the subsequent development of penicillin during World War II ushered in a new era in the treatment of infectious diseases. Infections that were common causes of death and disease in the pre-...antibiotic era - rheumatic fever, syphilis, cellulitis and bacterial pneumonia - became treatable, and over the next 20 years most of the classes of antibiotics that find clinical use today were discovered and changed medicine in a profound way. The availability of antibiotics enabled revolutionary medical interventions such as cancer chemotherapy, organ transplants and essentially all major invasive surgeries from joint replacements to coronary bypass. Antibiotics, though, are unique among drugs in that their use precipitates their obsolescence. Paradoxically, these cures select for organisms that can evade them, fueling an arms race between microbes, clinicians and drug discoverers.
Wright BMC Biology 2010, 8:123 http://www.biomedcentral.com/1741-7007/8/12
more
Harm reduction: evidence, impacts and challenges
-10-
CBR Advisory Working Group | Co-ordinator: Karen Heinicke-Motsch
Guidance Note A DFID practice paper
Updated to Reflect the 2009 Medical Eligibility Criteria of the World Health Organization
The English terminology, and its translations into Arabic, Chinese, French, Russian, and Spanish, are available on the UNISDR website at: www.unisdr.org/publications and on PreventionWeb at: www.preventionweb.net
Mortality and burden of disease attributable to selected major risks